Monte Rosa (GLUE): Avoro Reports 6.1% Stake — 3,725,000 Shares

Rhea-AI Filing Summary

Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 3,725,000 shares of Monte Rosa Therapeutics common stock, representing 6.1% of the class. The reporting persons state they have sole voting and sole dispositive power over these shares and that the shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.

The percentage is calculated using 61,509,821 shares outstanding as of May 5, 2025, per the company's quarterly report. The filing includes a certification that the securities were acquired in the ordinary course of business and were not acquired to change or influence control; signatures appear for Avoro and for Behzad Aghazadeh.

Positive

• 3,725,000 shares disclosed, representing a 6.1% stake in Monte Rosa Therapeutics
• Sole voting and sole dispositive power reported for the full position
• Shares are held on behalf of Avoro Life Sciences Fund LLC and described as acquired solely for investment purposes

Negative

• No purchase price or transaction dates are disclosed, limiting assessment of cost basis and recent activity
• Filing does not provide details on any future intentions beyond certification of passive investment

Insights

Financial Analyst

TL;DR: Avoro discloses a material 6.1% passive stake (3.725M shares); no stated intent to seek control.

The Schedule 13G/A shows a >5% position, which is material and must be monitored because it can influence market perception and liquidity for GLUE stock. The filing explicitly states sole voting and dispositive power for 3,725,000 shares and that holdings are on behalf of Avoro Life Sciences Fund LLC for investment purposes. The absence of transaction prices or timing in the filing limits assessment of cost basis and recent trading activity. Overall, this is a significant passive ownership disclosure rather than an active governance move.

Corporate Governance Expert

TL;DR: A significant non-activist stake is disclosed with formal certification denying control intentions.

The report identifies Avoro as the investment adviser and Dr. Aghazadeh as the portfolio manager and controlling person, with sole voting and dispositive authority over the disclosed shares. The filing follows Schedule 13G conventions for passive investors by certifying ordinary-course acquisition and no intent to change control. From a governance perspective, the disclosure notifies the market of influence potential but does not, by itself, indicate any planned engagement or board intentions.

FAQ

What stake did Avoro Capital report in Monte Rosa Therapeutics (GLUE)?

The filing reports 3,725,000 shares, equal to 6.1% of the outstanding common stock.

Who are the reporting persons on this Schedule 13G/A for GLUE?

The statement is filed by Avoro Capital Advisors LLC and Behzad Aghazadeh (the portfolio manager and controlling person).

On whose behalf are the shares held?

The shares were acquired on behalf of Avoro Life Sciences Fund LLC, per the filing.

How was the 6.1% ownership percentage calculated?

The percentage uses 61,509,821 shares outstanding as of May 5, 2025, per the company's quarterly report referenced in the filing.

Does the filing indicate an intent to influence control of Monte Rosa (GLUE)?

No. The filing includes a certification that the securities were acquired in the ordinary course of business and were not acquired to change or influence control of the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 07:10 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Monte Rosa Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

61225M102

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 61225M102

1

Names of Reporting Persons

Avoro Capital Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,725,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,725,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,725,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 61225M102

1

Names of Reporting Persons

Behzad Aghazadeh

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,725,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,725,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,725,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Monte Rosa Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 321 Harrison Avenue, Suite 900, Boston, MA 02118
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro"), which provides investment advisory and management services and has acquired the shares of common stock, par value $0.0001 per share ("Common Stock") of Monte Rosa Therapeutics, a Delaware corporation (the "Company"), solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh ("Dr. Aghazadeh," and together with Avoro, the "Reporting Persons"), who serves as the portfolio manager and controlling person of Avoro. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.
(c)	Citizenship: Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 61225M102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 61,509,821 shares of Common Stock outstanding as of May 5, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 8, 2025.
(b)	Percent of class: 6.1%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the shares of Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Avoro Capital Advisors LLC

Signature:	/s/ Scott Epstein
Name/Title:	Scott Epstein, Chief Financial Officer & Chief Compliance Officer
Date:	08/14/2025

Behzad Aghazadeh

Signature:	/s/ Behzad Aghazadeh
Name/Title:	Behzad Aghazadeh, Individually
Date:	08/14/2025